Understand Me for Life: Using Noise-augmented Automatic Speech Recognition to Improve Intelligibility in Parkinson's Disease

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The goal of this clinical trial is to learn whether noise-augmented feedback using automatic speech recognition improves intelligibility and social participation in individuals with Parkinson's disease. The main questions the investigators will address are: Does noise-augmented feedback lead to increased intelligibility, as measured by transcription accuracy scores? Does a self-managed speech protocol lead to increased social participation, as measured by the Communicative Participation Item Bank and the Communicative Effectiveness Index questionnaires? Participants will: Receive 2-4 initial speech assessments in-person in our lab. Engage in speech treatment sessions at home using their phone and computer four days a week for four weeks. Four of those sessions will be directly monitored online by a speech-language pathologist. The rest of the sessions are completed by the participant. Come to the lab for two post-treatment assessments following completion of treatment. Come to the lab six months after treatment completion for an additional assessment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:

• Participants will qualify for the study if:

‣ They are 50-80 years old,

⁃ They have a medical diagnosis of PD,

⁃ They are within stages I-IV of Hoehn \& Yahr Scale,

⁃ Their antiparkinsonian medication schedule is stable,

⁃ They present with mild to moderate dysarthria,

⁃ They score ≥ 25 in the MMSE,

⁃ They score ≤ 24 in the BDI-III.

Locations
United States
New York
Teachers College, Columbia University
RECRUITING
New York
Contact Information
Primary
Gemma Moya-Galé, Ph.D.
gm2446@tc.columbia.edu
212-678-3323
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 42
Treatments
Experimental: Immediate treatment
Participants will receive speech treatment immediately after their second pre-treatment assessment.
Active_comparator: Deferred treatment
Participants will receive speech treatment one month after their second pre-treatment assessment. This arm receives the same speech treatment as Arm 1.
Related Therapeutic Areas
Sponsors
Collaborators: Temple University
Leads: Teachers College, Columbia University

This content was sourced from clinicaltrials.gov